Effects of site-specific polyethylene glycol modification of recombinant human granulocyte colony-stimulating factor on its biologic activities

BioDrugs

Volumn 20, Issue 6, 2006, Pages 357-362

  Hao, Yong ^a   Chen, Junhui ^a   Wang, Xinchang ^a   Zhu, Haowen ^b   Rong, Zhigang ^b  

^a NANJING UNIVERSITY   (China)

^b Biopharmaceutical Institute of Jiangsu Wuzhong   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; MACROGOL; MALEIMIDE; MONOMETHOXY POLYETHYLENE GLYCOL MALEIMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG EFFECT; DRUG HALF LIFE; DRUG STABILITY; ENZYME DEGRADATION; GRANULOPOIESIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; TEMPERATURE;

EID: 33846172729     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200620060-00006     Document Type: Article

References (26)

1. Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drug Deliver Rev 1995; 16: 157-82
2. Greenwald RB, Choe YH, McGuire J, et al. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliver Rev 2003; 55: 217-50
3. Greenwald RB. PEG drugs: an overview. J Control Release 2001; 74: 159-71
4. Metcalf D. The hemopoietic colony stimulating factors. Amsterdam: Elsevier, 1984
5. Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907-29
6. Lie AKW, Hui CH, Rawling T, et al. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transpl 1998; 22 (9): 853-7
7. Fukumasu Y, Fukumasu H, Yamamasu S, et al. Stimulation of fetal granulopoiesis by intrauterine injection of recombinant human granulocyte colony-stimulating factor into rat fetuses. Biol Neonate 1999; 75 (6): 367-76
8. Haithcox S, Ramnes CR, Lee H, et al. The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs 2003; 2: 2
9. Morstyn G, Foote M, Walker T, et al. Filgrastim (r-metHuG-CSF) in the 21st century: SD/ 01. Acta Haematol 2001; 105: 151-5
10. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration PEG filgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-31
11. King DJ, Turner A, Farnsworth APH, et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994; 54: 6176-85
12. Bishop B, Koay DC, Sartorelli AC, et al. Reengineering granulocyte colony-stimulating factor for enhanced stability. J Biol Chem 2001; 276 (36): 33465-70
13. Cantin AM, Woods DE, Cloutier D, et al. Polyethylene glycol conjugation at Cys232 prolongs the half-life of α1 proteinase inhibitor. Am J Respir Cell Mol Biol 2002; 27: 659-65
14. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002; 54: 459-76
15. Colgstone CL, Boone TC, Souza LN, et al. Disulfide and secondary structures of recombinant human granulocyte colony-stimulating factor. Arch Biochem Biophys 1989; 268: 81-92
16. Kubota N, Orita T, Hattori K, et al. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem (Tokyo) 1990; 107 (3): 486-92
17. Matsuda S, Shirafuji N, Asano S. Human granulocyte colony-stimulating factor specifically binds to murine myeloblastic NFS-60 cells and activates their guanosine triphosphate binding proteins/adenylate cyclase system. Blood 1989; 74: 2343-8
18. Bowen S, Tare N, Inoue T, et al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp Hematol 1999; 27: 425-32
19. Kinstler OB, Brems DN, Lauren SL, et al. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharmaceut Res 1996; 13: 996-1002
20. de Haan G, Ausema A, Wilkens M, et al. Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes. Br J Haematol 2000; 110: 638-46
21. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001; 15 (7): 419-29
22. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-21
23. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2002; 22: 405-17
24. Goodson RJ, Katre NV. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology (NY) 1990; 8: 343-6
25. Kurfurst MM. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 1992; 200 (2): 244-8
26. Johnston E, Crawford J, Blackwell S, et al. Randomized, doseescalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-8